Cannabis player Althea divests MyAccess Clinics to focus on North American retail business

The Market Herald
29 Oct 2024

Althea Group Holdings Ltd (ASX:AGH) – a company focused on the manufacturing and retail of cannabis products – has sold its MyAccess Clinics business in the United Kingdom and Ireland to Montu UK Ltd for $1 million as part of a streamlining plan.

MyAccess provided medical cannabis treatments to help patients dealing with chronic pain, mental health and sleep conditions.

The sale is expected to allow Althea to achieve operating cost savings of around $1.5 million, as well as annualised cost savings of $4 million, previously announced in May.

On top of that, the company will now be able to concentrate more on expansion of its North American operations, particularly targeting the cannabis beverage sector through Peak Processing Solutions – its recreational cannabis business whose products are marketed to retail stores.

Althea CEO Joshua Fegan said the decision would boost the company’s ability to grow in North America in particular.

“The completion of this sale marks a significant step in AGH’s strategy to streamline our operations and sharpen our focus on high-growth opportunities,” he said.

“By divesting MyAccess Clinics, we are better positioned to accelerate our North American expansion, particularly in the cannabis beverages market through Peak Processing Solutions.”

Althea has been trading at 4.3 cents.

Join the discussion: See what HotCopper users are saying about Althea and be part of the conversations that move the markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10